TEOFIL Sub Q 1.1 ml
TEOFIL (Teofil)
Medical device — hyaluronic acid dermal fillerMonophasic HA dermal filler for deep dermis / subcutaneous volumising (contouring)
Certifications
- CE certified (manufacturer brochure explicitly states CE certification for the TEOFIL family; brochure indicates compliance with medical device regulations for CE marking).
- Manufacturer states ISO 13485 quality management compliance.
- Manufacturer claims HCCL™ manufacturing minimizes residual BDDE and delivers a stabilized 3D matrix (manufacturer technical claims in brochure).
- Clinical trial summary included in manufacturer brochure indicating comparative testing vs. reference device (brochure pages summarise clinical/efficacy assessments).
- CE certified (manufacturer brochure explicitly states CE certification for the TEOFIL family; brochure indicates compliance with medical device regulations for CE marking).
- Manufacturer states ISO 13485 quality management compliance.
- Manufacturer claims HCCL™ manufacturing minimizes residual BDDE and delivers a stabilized 3D matrix (manufacturer technical claims in brochure).
- Clinical trial summary included in manufacturer brochure indicating comparative testing vs. reference device (brochure pages summarise clinical/efficacy assessments).
Monophasic HA dermal filler for deep dermis / subcutaneous volumising (contouring)
Description
TEOFIL Sub-Q is a CE-certified, monophasic cross-linked hyaluronic acid (HA) filler manufactured using HCCL™ (Highly Completed Cross-Linking) technology. Formulated as a high-viscosity, viscoelastic gel for deep dermal and subcutaneous placement, Sub-Q is designed to restore lost facial volume and enhance contours in areas such as the chin, jawline and cheeks. The product is supplied in a prefilled syringe (1.1 ml) and includes lidocaine (0.3%) to increase patient comfort during injection. Manufacturer product literature states CE classification as a Class III medical device and lists composition, recommended injection depth and pack contents.
Bnefits
- High-viscosity monophasic gel providing structural support for facial contouring (chin, jawline, cheeks)
- HCCL™ advanced cross-linking manufacturing process claimed to improve stability and minimize pendant BDDE
- Contains lidocaine (0.3%) for reduced injection discomfort
- 20 mg HA per ml concentration for volumising and hydration
- Supplied as a ready-to-use prefilled syringe with recommended needle gauges for clinical use
- CE marked (manufacturer-stated) and produced under ISO 13485 quality processes per manufacturer literature
Indications
- Enhancement of facial contours and restoration of lost volume (chin, jawline, cheeks)
- Volumising applications requiring durable structural support via medium-to-deep/subcutaneous placement
- General facial contouring where a high-viscosity HA filler is clinically indicated
Composition
- Cross-linked hyaluronic acid (HA) — 20 mg/ml (manufacturer product summary)
- Lidocaine — 0.3% (manufacturer product summary)
- Cross-linking performed via HCCL™ manufacturing process (manufacturer claim; exact cross-linker residuals not published)
Formulation
- Monophasic hyaluronic acid gel with enhanced viscoelasticity for deep/subcutaneous injection
- Prefilled sterile syringe (1.1 ml) intended for single use
- Pack includes recommended needle gauges (manufacturer product summary lists 1 x 25G needle and 1 x 27G needle for Sub-Q)
Packaging
- Typically supplied as 1 x 1.1 ml prefilled syringe in sterile single-use packaging (manufacturer brochure / distributor listings)
- Individual syringe packaged with needles and product leaflet; carton and artwork may vary by region and distributor
Usage
- For professional use only by qualified practitioners trained in injectable dermal fillers (manufacturer/distributor pages state 'Professional Use Only').
- Use aseptic technique and follow the manufacturer's instructions for injection depth and technique (Sub-Q is intended for deep dermal to subcutaneous/periosteal placement).
- Select appropriate needle/cannula size as recommended in product literature; manufacturer lists 25G and 27G needles in pack contents for Sub-Q.
- Inspect packaging integrity prior to use; follow local protocols for patient selection, informed consent, and post-procedure care.
- Follow local sharps disposal and infection-control procedures and monitor patients for adverse events post-injection.
Contraindications
Not publicly listed
Adverse Effects
Not publicly listed
Storage Conditions
- Manufacturer/distributor materials reference standard storage in original packaging, protected from extreme temperatures and direct sunlight; consult product labelling/IFU for exact temperature range.
- Keep sterile until use and store in a clean, dry place as indicated on carton/leaflet.
Duration
Not publicly listed (manufacturer/distributor materials describe 'long-lasting' results; no fixed duration guarantee is published \u2014 clinical duration depends on individual factors and is variable)
Onset
Not publicly listed (immediate visible volumising/smoothing effect expected upon injection; brochure does not quantify onset time)
| Price | Link |
|---|---|
| £16.49 | https://www.lpgclinicswholesale.com/product/teofil-sub-q/ |
